SENS - Senseonics Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
2.0600
+0.0600 (+3.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.0000
Open2.0300
Bid0.0000 x 2200
Ask0.0000 x 2900
Day's Range2.0161 - 2.0800
52 Week Range1.7400 - 5.2900
Volume975,294
Avg. Volume1,587,417
Market Cap364.636M
Beta (3Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-0.6040
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.72
Trade prices are not sourced from all markets
  • One Thing To Remember About The Senseonics Holdings, Inc. (NYSEMKT:SENS) Share Price
    Simply Wall St.14 hours ago

    One Thing To Remember About The Senseonics Holdings, Inc. (NYSEMKT:SENS) Share Price

    Anyone researching Senseonics Holdings, Inc. (NYSEMKT:SENS) might want to consider the historical volatility of the...

  • Thomson Reuters StreetEvents4 days ago

    Edited Transcript of SENS earnings conference call or presentation 9-May-19 8:30pm GMT

    Q1 2019 Senseonics Holdings Inc Earnings Call

  • Business Wire12 days ago

    Senseonics Announces FDA Approval for a Non-Adjunctive Indication (Dosing Claim) for the Eversense® 90-day CGM System

    Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that they received FDA approval for the non-adjunctive indication (dosing claim) for the Eversense Continuous Glucose Monitoring System. Patients will soon be able to use Eversense as a replacement for fingersticks to make diabetes treatment decisions throughout the day.

  • Business Wire13 days ago

    Senseonics to Present Real-World, Long-Term Safety Data of the First Implantable CGM Sensor at the American Diabetes Association’s 79th Scientific Sessions

    Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, will present the long-term safety data of the Eversense CGM System derived from its Post Market Clinical Follow Up (PMCF) registry in Europe. The poster is to be presented by Katherine Tweden, PhD on Saturday, June 8 from 11:30 am – 12:30 pm in Hall F of the North Exhibition building during the annual American Diabetes Association Scientific Sessions held in San Francisco. “We are pleased with the results of the European Eversense PMCF registry which demonstrate the safety of the Eversense CGM System in a large group of patients,” said Katherine Tweden, PhD, Vice President of Clinical Sciences at Senseonics.

  • Business Wire14 days ago

    Senseonics to Participate in the Raymond James Life Sciences and MedTech Conference

    Senseonics Holdings, Inc. , a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, today announced the company plans to participate in the upcoming Raymond James Life Sciences and MedTech Conference in New York, NY.

  • Business Wire28 days ago

    Senseonics to Participate in the Guggenheim MedTech Disruptors Summit

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the company plans to participate in the upcoming Guggenheim MedTech Disruptors Summit in New York, NY. Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease.

  • Senseonics Holdings, Inc. (SENS) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    Senseonics Holdings, Inc. (SENS) Q1 2019 Earnings Call Transcript

    SENS earnings call for the period ending March 31, 2019.

  • What You Need to Know About Senseonics Holdings' Q1 Earnings Update
    Motley Foollast month

    What You Need to Know About Senseonics Holdings' Q1 Earnings Update

    The continuous glucose system (CGM) maker posted solid revenue growth but missed Wall Street's revenue and earnings estimates.

  • Were Hedge Funds Right About Dumping Senseonics Holdings, Inc. (SENS) ?
    Insider Monkeylast month

    Were Hedge Funds Right About Dumping Senseonics Holdings, Inc. (SENS) ?

    Does Senseonics Holdings, Inc. (NYSE:SENS) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend […]

  • Senseonics Holdings (SENS) Reports Q1 Loss, Lags Revenue Estimates
    Zackslast month

    Senseonics Holdings (SENS) Reports Q1 Loss, Lags Revenue Estimates

    Senseonics (SENS) delivered earnings and revenue surprises of -41.67% and -15.38%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Senseonics: 1Q Earnings Snapshot

    On a per-share basis, the Germantown, Maryland-based company said it had a loss of 17 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Business Wirelast month

    Senseonics Holdings, Inc. Reports First Quarter 2019 Financial Results

    Senseonics Holdings, Inc. , a medical technology company focused on the design, development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, today reported financial results for the quarter ended March 31, 2019.

  • Will Senseonics Holdings (SENS) Report Negative Earnings Next Week? What You Should Know
    Zacks2 months ago

    Will Senseonics Holdings (SENS) Report Negative Earnings Next Week? What You Should Know

    Senseonics (SENS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire2 months ago

    Senseonics Holdings, Inc. Schedules First Quarter 2019 Earnings Release and Conference Call for May 9, 2019 at 4:30 p.m. Eastern Time

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it plans to release its first quarter 2019 financial results after market close on Thursday, May 9, 2019. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease.

  • Senseonics Unveils Eversense Bridge Program in the U.S.
    Zacks3 months ago

    Senseonics Unveils Eversense Bridge Program in the U.S.

    The Eversense Bridge program aligns with Senseonics' (SENS) strategy of offering innovative yet affordable and hassle-free medical care to diabetic patients.

  • Business Wire3 months ago

    Senseonics Launches the Eversense® Bridge Patient Access Program in the U.S.

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, has announced the launch of the Eversense Bridge Program. Under the program, patients can access the Eversense CGM System, the only long-term CGM that lasts up to 90 days, for only $99* plus the cost of the sensor placement by the healthcare provider. “The Eversense Bridge Program is an important strategic initiative with the goal of providing access to eligible patients who have high out-of-pocket costs, are waiting for a favorable coverage policy, or have been denied insurance coverage for Eversense,” said Tim Goodnow, President and CEO of Senseonics.

  • Is the Options Market Predicting a Spike in Senseonics Holdings (SENS) Stock?
    Zacks3 months ago

    Is the Options Market Predicting a Spike in Senseonics Holdings (SENS) Stock?

    Investors need to pay close attention to Senseonics Holdings (SENS) stock based on the movements in the options market lately.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of SENS earnings conference call or presentation 12-Mar-19 8:30pm GMT

    Q4 2018 Senseonics Holdings Inc Earnings Call

  • What Kind Of Share Price Volatility Should You Expect For Sensor Technologies Corp. (CNSX:SENS)?
    Simply Wall St.3 months ago

    What Kind Of Share Price Volatility Should You Expect For Sensor Technologies Corp. (CNSX:SENS)?

    If you own shares in Sensor Technologies Corp. (CNSX:SENS) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...

  • Senseonics Holdings, Inc. (SENS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Senseonics Holdings, Inc. (SENS) Q4 2018 Earnings Conference Call Transcript

    SENS earnings call for the period ending December 31, 2018.

  • Senseonics Holdings (SENS) Reports Q4 Loss, Lags Revenue Estimates
    Zacks3 months ago

    Senseonics Holdings (SENS) Reports Q4 Loss, Lags Revenue Estimates

    Senseonics (SENS) delivered earnings and revenue surprises of 73.33% and -8.75%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Senseonics: 4Q Earnings Snapshot

    The Germantown, Maryland-based company said it had a loss of 4 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • Business Wire3 months ago

    Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results

    Senseonics Holdings, Inc. , a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring system for people with diabetes, today reported financial results for the fourth quarter and full year ended December 31, 2018.

  • Did Changing Sentiment Drive Senseonics Holdings’s (NYSEMKT:SENS) Share Price Down By 16%?
    Simply Wall St.3 months ago

    Did Changing Sentiment Drive Senseonics Holdings’s (NYSEMKT:SENS) Share Price Down By 16%?

    Senseonics Holdings, Inc. (NYSEMKT:SENS) shareholders should be happy to see the share price up 27% in the last month. But that doesn't change the fact that the returns over theRead More...

  • Business Wire3 months ago

    Senseonics Announces Appointment of Francine R. Kaufman, M.D. as Chief Medical Officer

    Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the appointment of Francine R. Kaufman, M.D. as Chief Medical Officer, effective immediately. “We are pleased to have Fran join the executive leadership team at Senseonics. As Chief Medical Officer, she will be instrumental in helping drive forward our innovation platform and the clinical value proposition of the Eversense system,” said Tim Goodnow, President and CEO of Senseonics.